Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Recurring Glioblastoma: A Case for Reoperation?.

Dejaegher J, De Vleeschouwer S.

In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 14.

2.

Glioblastoma: To Target the Tumor Cell or the Microenvironment?.

De Vleeschouwer S, Bergers G.

In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 16.

3.

Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.

Mathivet T, Bouleti C, Van Woensel M, Stanchi F, Verschuere T, Phng LK, Dejaegher J, Balcer M, Matsumoto K, Georgieva PB, Belmans J, Sciot R, Stockmann C, Mazzone M, De Vleeschouwer S, Gerhardt H.

EMBO Mol Med. 2017 Dec;9(12):1629-1645. doi: 10.15252/emmm.201607445.

4.

Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.

Dejaegher J, Verschuere T, Vercalsteren E, Boon L, Cremer J, Sciot R, Van Gool SW, De Vleeschouwer S.

Int J Cancer. 2017 Nov 1;141(9):1891-1900. doi: 10.1002/ijc.30877. Epub 2017 Jul 19.

PMID:
28681455
5.

Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.

Garg AD, Vandenberk L, Van Woensel M, Belmans J, Schaaf M, Boon L, De Vleeschouwer S, Agostinis P.

Oncoimmunology. 2017 Mar 3;6(4):e1295903. doi: 10.1080/2162402X.2017.1295903. eCollection 2017.

6.

Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.

Van Woensel M, Mathivet T, Wauthoz N, Rosière R, Garg AD, Agostinis P, Mathieu V, Kiss R, Lefranc F, Boon L, Belmans J, Van Gool SW, Gerhardt H, Amighi K, De Vleeschouwer S.

Sci Rep. 2017 Apr 27;7(1):1217. doi: 10.1038/s41598-017-01279-1.

7.

Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.

Vandenberk L, Garg AD, Verschuere T, Koks C, Belmans J, Beullens M, Agostinis P, De Vleeschouwer S, Van Gool SW.

Oncoimmunology. 2015 Sep 11;5(2):e1083669. eCollection 2016 Feb.

8.

Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.

Van Woensel M, Wauthoz N, Rosière R, Mathieu V, Kiss R, Lefranc F, Steelant B, Dilissen E, Van Gool SW, Mathivet T, Gerhardt H, Amighi K, De Vleeschouwer S.

J Control Release. 2016 Apr 10;227:71-81. doi: 10.1016/j.jconrel.2016.02.032. Epub 2016 Feb 21.

PMID:
26902800
9.

A posttraumatic pontomedullary rent with good outcome.

De Vloo P, Declerck L, Stevens O, De Vleeschouwer S.

Acta Neurochir (Wien). 2016 Mar;158(3):577-9. doi: 10.1007/s00701-016-2712-9. Epub 2016 Jan 22.

PMID:
26801511
10.

Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.

Müller K, Henke G, Pietschmann S, van Gool S, De Vleeschouwer S, von Bueren AO, Compter I, Friedrich C, Matuschek C, Klautke G, Kortmann RD, Hundsberger T, Baumert BG.

J Neurooncol. 2015 Sep;124(2):325-32. doi: 10.1007/s11060-015-1844-8. Epub 2015 Jun 13.

PMID:
26070556
11.

Living with a high-grade glioma: A qualitative study of patients' experiences and care needs.

Sterckx W, Coolbrandt A, Clement P, Borgenon S, Decruyenaere M, De Vleeschouwer S, Mees A, Dierckx de Casterlé B.

Eur J Oncol Nurs. 2015 Aug;19(4):383-90. doi: 10.1016/j.ejon.2015.01.003. Epub 2015 Feb 16.

PMID:
25697546
12.

Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?

Koks CA, De Vleeschouwer S, Graf N, Van Gool SW.

J Cancer. 2015 Jan 15;6(3):203-17. doi: 10.7150/jca.10640. eCollection 2015. Review.

13.

Results of endoscopic third ventriculostomy in elderly patients ≥65 years of age.

Niknejad HR, Depreitere B, De Vleeschouwer S, Van Calenbergh F, van Loon J.

Clin Neurol Neurosurg. 2015 Mar;130:48-54. doi: 10.1016/j.clineuro.2014.12.009. Epub 2014 Dec 31.

PMID:
25576885
14.

Family Caregivers of Patients With a High-Grade Glioma: A Qualitative Study of Their Lived Experience and Needs Related to Professional Care.

Coolbrandt A, Sterckx W, Clement P, Borgenon S, Decruyenaere M, de Vleeschouwer S, Mees A, Dierckx de Casterlé B.

Cancer Nurs. 2015 Sep-Oct;38(5):406-13. doi: 10.1097/NCC.0000000000000216.

PMID:
25521908
15.

Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.

Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, De Vleeschouwer S, Agostinis P, Graf N, Van Gool SW.

Int J Cancer. 2015 Mar 1;136(5):E313-25. doi: 10.1002/ijc.29202. Epub 2014 Sep 19.

16.

Letter: Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery.

De Vleeschouwer S.

Eur J Surg Oncol. 2014 Oct;40(10):1384-5. doi: 10.1016/j.ejso.2014.04.018. Epub 2014 Jul 4. No abstract available.

PMID:
25085793
17.

Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.

Eyrich M, Schreiber SC, Rachor J, Krauss J, Pauwels F, Hain J, Wölfl M, Lutz MB, de Vleeschouwer S, Schlegel PG, Van Gool SW.

Cytotherapy. 2014 Jul;16(7):946-64. doi: 10.1016/j.jcyt.2014.02.017. Epub 2014 May 13.

PMID:
24831836
18.

Primary brain tumours, meningiomas and brain metastases in pregnancy: report on 27 cases and review of literature.

Verheecke M, Halaska MJ, Lok CA, Ottevanger PB, Fruscio R, Dahl-Steffensen K, Kolawa W, Gziri MM, Han SN, Van Calsteren K, Van den Heuvel F, De Vleeschouwer S, Clement PM, Menten J, Amant F; ESGO Task Force ‘Cancer in Pregnancy’.

Eur J Cancer. 2014 May;50(8):1462-71. doi: 10.1016/j.ejca.2014.02.018. Epub 2014 Mar 14. Review.

PMID:
24636876
19.

Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.

Dejaegher J, Van Gool S, De Vleeschouwer S.

Immunotargets Ther. 2014 Mar 13;3:55-66. doi: 10.2147/ITT.S40121. eCollection 2014. Review.

20.

Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

van Woensel M, Wauthoz N, Rosière R, Amighi K, Mathieu V, Lefranc F, van Gool SW, de Vleeschouwer S.

Cancers (Basel). 2013 Aug 14;5(3):1020-48. doi: 10.3390/cancers5031020.

21.

Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.

Verschuere T, Toelen J, Maes W, Poirier F, Boon L, Tousseyn T, Mathivet T, Gerhardt H, Mathieu V, Kiss R, Lefranc F, Van Gool SW, De Vleeschouwer S.

Int J Cancer. 2014 Feb 15;134(4):873-84. doi: 10.1002/ijc.28426. Epub 2013 Sep 4.

22.

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, Van Gool SW, De Vleeschouwer S.

J Neurooncol. 2013 Oct;115(1):9-17. doi: 10.1007/s11060-013-1201-8. Epub 2013 Jul 4.

PMID:
23824536
23.

Defining pseudoprogression in glioblastoma multiforme.

Van Mieghem E, Wozniak A, Geussens Y, Menten J, De Vleeschouwer S, Van Calenbergh F, Sciot R, Van Gool S, Bechter OE, Demaerel P, Wilms G, Clement PM.

Eur J Neurol. 2013 Oct;20(10):1335-41. doi: 10.1111/ene.12192. Epub 2013 May 17.

PMID:
23679051
24.

Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

Van Gool S, De Vleeschouwer S.

Expert Rev Neurother. 2012 Oct;12(10):1173-6. doi: 10.1586/ern.12.107. No abstract available.

PMID:
23082731
25.

Ependymomas of the filum terminale: The role of surgery and radiotherapy.

de Jong L, Calenbergh FV, Menten J, van Loon J, De Vleeschouwer S, Plets C, Didgar M, Sciot R, Goffin J.

Surg Neurol Int. 2012;3:76. doi: 10.4103/2152-7806.98509. Epub 2012 Jul 14.

26.

Galectin-1 in melanoma biology and related neo-angiogenesis processes.

Mathieu V, de Lassalle EM, Toelen J, Mohr T, Bellahcène A, Van Goietsenoven G, Verschuere T, Bouzin C, Debyser Z, De Vleeschouwer S, Van Gool S, Poirier F, Castronovo V, Kiss R, Feron O.

J Invest Dermatol. 2012 Sep;132(9):2245-54. doi: 10.1038/jid.2012.142. Epub 2012 May 24.

27.

Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.

De Vleeschouwer S, Ardon H, Van Calenbergh F, Sciot R, Wilms G, van Loon J, Goffin J, Van Gool S.

Cancer Immunol Immunother. 2012 Nov;61(11):2105-12. doi: 10.1007/s00262-012-1271-z. Epub 2012 May 8.

PMID:
22565485
28.

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.

Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S.

Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.

PMID:
22527250
29.

Gliomas: diffusion kurtosis MR imaging in grading.

Van Cauter S, Veraart J, Sijbers J, Peeters RR, Himmelreich U, De Keyzer F, Van Gool SW, Van Calenbergh F, De Vleeschouwer S, Van Hecke W, Sunaert S.

Radiology. 2012 May;263(2):492-501. doi: 10.1148/radiol.12110927. Epub 2012 Mar 8.

PMID:
22403168
30.

Galectin-1 and immunotherapy for brain cancer.

Verschuere T, De Vleeschouwer S, Lefranc F, Kiss R, Van Gool SW.

Expert Rev Neurother. 2011 Apr;11(4):533-43. doi: 10.1586/ern.11.40. Review.

PMID:
21469926
31.

Long-lasting, complete exclusion of a large galenic dural arteriovenous fistula after clipping of the central venous aneurysm of the vein of galen: case report.

De Vleeschouwer S, Smets CA, Wilms G.

Neurosurgery. 2011 Feb;68(2):E571-4; discussion E574. doi: 10.1227/NEU.0b013e318202088a.

PMID:
21135725
32.

MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study.

Vrabec M, Van Cauter S, Himmelreich U, Van Gool SW, Sunaert S, De Vleeschouwer S, Suput D, Demaerel P.

Neuroradiology. 2011 Oct;53(10):721-31. doi: 10.1007/s00234-010-0802-6. Epub 2010 Nov 25.

PMID:
21107549
33.

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.

Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S.

J Neurooncol. 2010 Sep;99(2):261-72. doi: 10.1007/s11060-010-0131-y. Epub 2010 Feb 10.

PMID:
20146084
34.

Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination.

Ardon H, Verbinnen B, Maes W, Beez T, Van Gool S, De Vleeschouwer S.

J Immunol Methods. 2010 Jan 31;352(1-2):169-73. doi: 10.1016/j.jim.2009.10.007. Epub 2009 Oct 27.

PMID:
19874827
35.

Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours.

Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, Wolff JE, Van Gool SW.

Pediatr Blood Cancer. 2010 Apr;54(4):519-25. doi: 10.1002/pbc.22319.

PMID:
19852061
36.

Dendritic cell therapy of high-grade gliomas.

Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S.

Brain Pathol. 2009 Oct;19(4):694-712. doi: 10.1111/j.1750-3639.2009.00316.x. Review.

PMID:
19744041
37.

DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, Van Gool SW.

Neuro Oncol. 2009 Oct;11(5):529-42. doi: 10.1215/15228517-2009-004. Epub 2009 Mar 31.

38.

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.

De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW.

Clin Cancer Res. 2008 May 15;14(10):3098-104. doi: 10.1158/1078-0432.CCR-07-4875.

39.

Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells.

De Vleeschouwer S, Spencer Lopes I, Ceuppens JL, Van Gool SW.

J Neurooncol. 2007 Sep;84(2):131-40. Epub 2007 Mar 15.

PMID:
17361330
40.

Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.

de Vleeschouwer S, Rapp M, Sorg RV, Steiger HJ, Stummer W, van Gool S, Sabel M.

Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000. Review.

PMID:
17143233
41.

Risk analysis of thrombo-embolic and recurrent bleeding events in the management of intracranial haemorrhage due to oral anticoagulation.

De Vleeschouwer S, Van Calenbergh F, van Loon J, Nuttin B, Goffin J, Plets C.

Acta Chir Belg. 2005 May-Jun;105(3):268-74.

PMID:
16018519
42.

Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells.

De Vleeschouwer S, Arredouani M, Adé M, Cadot P, Vermassen E, Ceuppens JL, Van Gool SW.

Cancer Immunol Immunother. 2005 Apr;54(4):372-82. Epub 2004 Oct 19.

PMID:
15692847
43.

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study.

Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kühl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sörensen N, Opitz A, Van Gool SW.

Br J Cancer. 2004 Nov 1;91(9):1656-62.

44.

Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

De Vleeschouwer S, Van Gool SW, Van Calenbergh F.

Childs Nerv Syst. 2005 Jan;21(1):7-18. Epub 2004 Sep 28. Review.

PMID:
15452731
45.

Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report.

De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciot R, Van Gool SW.

J Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7.

PMID:
15287461

Supplemental Content

Loading ...
Support Center